Literature DB >> 21544687

Oxidized and aggregated recombinant human interferon beta is immunogenic in human interferon beta transgenic mice.

Miranda M C van Beers1, Melody Sauerborn, Francesca Gilli, Vera Brinks, Huub Schellekens, Wim Jiskoot.   

Abstract

PURPOSE: To study the effect of oxidation on the structure of recombinant human interferon beta-1a (rhIFNβ-1a) and its immunogenicity in wild-type and immune-tolerant transgenic mice.
METHODS: Untreated rhIFNβ-1a was degraded by metal-catalyzed oxidation, H(2)O(2)-mediated oxidation, and guanidine-mediated unfolding/refolding. Four rhIFNβ-1a preparations with different levels of oxidation and aggregation were injected intraperitoneally in mice 15× during 3 weeks. Both binding and neutralizing antibodies were measured.
RESULTS: All rhIFNβ-1a preparations contained substantial amounts of aggregates. Metal-catalyzed oxidized rhIFNβ-1a contained high levels of covalent aggregates as compared with untreated rhIFNβ-1a. H(2)O(2)-treated rhIFNβ-1a showed an increase in oligomer and unrecovered protein content by HP-SEC; RP-HPLC revealed protein oxidation. Guanidine-treated rhIFNβ-1a mostly consisted of dimers and oligomers and some non-covalent aggregates smaller in size than those in untreated rhIFNβ-1a. All degraded samples showed alterations in tertiary protein structure. Wild-type mice showed equally high antibody responses against all preparations. Transgenic mice were discriminative, showing elevated antibody responses against both metal-catalyzed oxidized and H(2)O(2)-treated rhIFNβ-1a as compared to untreated and guanidine-treated rhIFNβ-1a.
CONCLUSIONS: Oxidation-mediated aggregation increased the immunogenicity of rhIFNβ-1a in transgenic mice, whereas aggregated preparations devoid of measurable oxidation levels were hardly immunogenic.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21544687      PMCID: PMC3170469          DOI: 10.1007/s11095-011-0451-4

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  30 in total

Review 1.  Bioequivalence and the immunogenicity of biopharmaceuticals.

Authors:  Huub Schellekens
Journal:  Nat Rev Drug Discov       Date:  2002-06       Impact factor: 84.694

2.  Neutralizing antibodies against interferon-Beta.

Authors:  Per Soelberg Sorensen
Journal:  Ther Adv Neurol Disord       Date:  2008-09       Impact factor: 6.570

Review 3.  Effects of protein aggregates: an immunologic perspective.

Authors:  Amy S Rosenberg
Journal:  AAPS J       Date:  2006-08-04       Impact factor: 4.009

4.  Development of HSA-free formulations for a hydrophobic cytokine with improved stability.

Authors:  Andrea Hawe; Wolfgang Friess
Journal:  Eur J Pharm Biopharm       Date:  2007-05-05       Impact factor: 5.571

5.  Structural and functional differences between glycosylated and non-glycosylated forms of human interferon-beta (IFN-beta).

Authors:  L Runkel; W Meier; R B Pepinsky; M Karpusas; A Whitty; K Kimball; M Brickelmaier; C Muldowney; W Jones; S E Goelz
Journal:  Pharm Res       Date:  1998-04       Impact factor: 4.200

6.  The influence of antigen organization on B cell responsiveness.

Authors:  M F Bachmann; U H Rohrer; T M Kündig; K Bürki; H Hengartner; R M Zinkernagel
Journal:  Science       Date:  1993-11-26       Impact factor: 47.728

7.  The immunogenicity of soluble haptenated polymers is determined by molecular mass and hapten valence.

Authors:  R Z Dintzis; M Okajima; M H Middleton; G Greene; H M Dintzis
Journal:  J Immunol       Date:  1989-08-15       Impact factor: 5.422

8.  Aggregated recombinant human interferon Beta induces antibodies but no memory in immune-tolerant transgenic mice.

Authors:  Miranda M C van Beers; Melody Sauerborn; Francesca Gilli; Vera Brinks; Huub Schellekens; Wim Jiskoot
Journal:  Pharm Res       Date:  2010-05-25       Impact factor: 4.200

Review 9.  The structure of human interferon-beta: implications for activity.

Authors:  M Karpusas; A Whitty; L Runkel; P Hochman
Journal:  Cell Mol Life Sci       Date:  1998-11       Impact factor: 9.261

10.  Hybrid transgenic immune tolerant mouse model for assessing the breaking of B cell tolerance by human interferon beta.

Authors:  Miranda M C van Beers; Melody Sauerborn; Francesca Gilli; Suzanne Hermeling; Vera Brinks; Huub Schellekens; Wim Jiskoot
Journal:  J Immunol Methods       Date:  2009-10-24       Impact factor: 2.303

View more
  33 in total

1.  In vivo fluorescence imaging of IgG1 aggregates after subcutaneous and intravenous injection in mice.

Authors:  Vasco Filipe; Ivo Que; John F Carpenter; Clemens Löwik; Wim Jiskoot
Journal:  Pharm Res       Date:  2013-08-15       Impact factor: 4.200

Review 2.  Oxidation of therapeutic proteins and peptides: structural and biological consequences.

Authors:  Riccardo Torosantucci; Christian Schöneich; Wim Jiskoot
Journal:  Pharm Res       Date:  2013-09-25       Impact factor: 4.200

3.  Comparative Evaluation of Two Methods for Preparative Fractionation of Proteinaceous Subvisible Particles--Differential Centrifugation and FACS.

Authors:  Björn Boll; Emilien Folzer; Christof Finkler; Jörg Huwyler; Hanns-Christian Mahler; Roland Schmidt; Atanas V Koulov
Journal:  Pharm Res       Date:  2015-07-21       Impact factor: 4.200

Review 4.  Proteolysis and Oxidation of Therapeutic Proteins After Intradermal or Subcutaneous Administration.

Authors:  Ninad Varkhede; Rupesh Bommana; Christian Schöneich; M Laird Forrest
Journal:  J Pharm Sci       Date:  2019-08-10       Impact factor: 3.534

Review 5.  Preclinical models used for immunogenicity prediction of therapeutic proteins.

Authors:  Vera Brinks; Daniel Weinbuch; Matthew Baker; Yann Dean; Philippe Stas; Stefan Kostense; Bonita Rup; Wim Jiskoot
Journal:  Pharm Res       Date:  2013-05-07       Impact factor: 4.200

6.  Purification and identification of high molecular weight products formed during storage of neutral formulation of human insulin.

Authors:  Christian Fogt Hjorth; František Hubálek; Jonatan Andersson; Christian Poulsen; Daniel Otzen; Helle Naver
Journal:  Pharm Res       Date:  2015-01-14       Impact factor: 4.200

7.  Effect of arginine on pre-nucleus stage of interferon beta-1b aggregation.

Authors:  Ahmad Fazeli; Mohadeseh Haji-Abdolvahab; Seyed Abbas Shojaosadati; Huub Schellekens; Khosro Khalifeh; Ali Akbar Moosavi-Movahedi; Mohammad Reza Fazeli
Journal:  AAPS PharmSciTech       Date:  2014-08-21       Impact factor: 3.246

8.  Physical Characterization and Innate Immunogenicity of Aggregated Intravenous Immunoglobulin (IGIV) in an In Vitro Cell-Based Model.

Authors:  E M Moussa; J Kotarek; J S Blum; E Marszal; E M Topp
Journal:  Pharm Res       Date:  2016-04-01       Impact factor: 4.200

9.  Mitigation of Oxidation in Therapeutic Antibody Formulations: a Biochemical Efficacy and Safety Evaluation of N-Acetyl-Tryptophan and L-Methionine.

Authors:  Michelle Z Dion; Danielle Leiske; Vikas K Sharma; Christina L Zuch de Zafra; Cleo M Salisbury
Journal:  Pharm Res       Date:  2018-10-02       Impact factor: 4.200

10.  Identification of oxidation sites and covalent cross-links in metal catalyzed oxidized interferon Beta-1a: potential implications for protein aggregation and immunogenicity.

Authors:  Riccardo Torosantucci; Victor S Sharov; Miranda van Beers; Vera Brinks; Christian Schöneich; Wim Jiskoot
Journal:  Mol Pharm       Date:  2013-05-02       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.